SCHEMBL23723711

SCHEMBL23723711

CNCC(=O)N1CCc2ccccc21

nearest known ligand 0.69

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.69
LMNA P02545 1/20 0.66
CYP3A4 P08684 1/20 0.66
L3MBTL1 Q9Y468 1/20 0.66
MAPT P10636 6/20 0.65
MEN1 O00255 2/20 0.65
KMT2A Q03164 2/20 0.65
NOTUM Q6P988 4/20 0.63
ALDH1A1 P00352 4/20 0.61
MAPK1 P28482 2/20 0.60
NPC1 O15118 3/20 0.57
RAB9A P51151 3/20 0.57
SMN1; SMN2 Q16637 3/20 0.57
HSD17B10 Q99714 2/20 0.57
POLB P06746 2/20 0.57
TP53 P04637 1/20 0.56
NFKB1 P19838 1/20 0.56
NFKB2 Q00653 1/20 0.56
RELA Q04206 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25333331 0.83 TSHR (0.67) TSHRLMNACYP3A4L3MBTL1MAPT
SCHEMBL14817503 0.83 TSHR (0.67) TSHRLMNACYP3A4L3MBTL1MAPT
SCHEMBL23409642 0.83 TSHR (0.71) TSHRLMNACYP3A4L3MBTL1MAPT
SCHEMBL5006023 0.82 TSHR (0.75) TSHRMAPTMEN1KMT2ANOTUM
SCHEMBL308295 0.81 NOTUM (0.74) TSHRLMNACYP3A4L3MBTL1MAPT
SCHEMBL1546073 0.80 TSHR (0.77) TSHRLMNACYP3A4L3MBTL1MAPT
SCHEMBL13041447 0.80 TSHR (0.67) TSHRLMNACYP3A4L3MBTL1MAPT
SCHEMBL8593659 0.80 NOTUM (0.79) TSHRLMNACYP3A4L3MBTL1MAPT
SCHEMBL8901483 0.80 NOTUM (0.65) TSHRLMNACYP3A4L3MBTL1MEN1
SCHEMBL4810543 0.80 LMNA (0.44) TSHRLMNACYP3A4L3MBTL1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230140216-A1 COMBINATION THERAPY FOR TREATING MPS1 GAIN THERAPEUTICS SA (CH) 2023-05-04 US disclosed
US-20230140216-A1 COMBINATION THERAPY FOR TREATING MPS1 GAIN THERAPEUTICS SA (CH) 2023-05-04 US disclosed
US-20230140216-A1 COMBINATION THERAPY FOR TREATING MPS1 GAIN THERAPEUTICS SA (CH) 2023-05-04 US disclosed
EP-4100015-A1 COMBINATION THERAPY FOR TREATING MPS1 Gain Therapeutics SA (CH) 2022-12-14 EP disclosed
WO-2021156774-A1 COMBINATION THERAPY FOR TREATING MPS1 GAIN THERAPEUTICS SA (CH) 2021-08-12 WO disclosed
WO-2021156774-A1 COMBINATION THERAPY FOR TREATING MPS1 GAIN THERAPEUTICS SA (CH) 2021-08-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230140216-A1 COMBINATION THERAPY FOR TREATING MPS1 IDUA, MAN2B1, GBA1 TSHR 1442/4885LMNA 560/4885CYP3A4 1477/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.